Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis.
CpG methylation
clear cell renal cell carcinoma
differential gene expression
metastasis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
09
06
2023
revised:
28
06
2023
accepted:
04
07
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive histological type of cancer in this location. Distant metastases are present in approximately 30% of patients at the time of first examination. Therefore, the ability to predict the occurrence of metastases in patients at early stages of the disease is an urgent task aimed at personalized treatment. Samples of tumor and paired histologically normal kidney tissue from patients with metastatic and non-metastatic ccRCC were studied. Gene expression was analyzed using real-time PCR. The level of gene methylation was evaluated using bisulfite conversion followed by quantitative methylation-specific PCR. Two groups of genes were analyzed in this study. The first group includes genes whose expression is significantly reduced during metastasis:
Identifiants
pubmed: 37443682
pii: diagnostics13132289
doi: 10.3390/diagnostics13132289
pmc: PMC10340761
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
In Vivo. 2023 Jan-Feb;37(1):1-10
pubmed: 36593023
J BUON. 2019 Nov-Dec;24(6):2341-2346
pubmed: 31983104
Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(9):57-62
pubmed: 36905274
Mol Cancer. 2013 Oct 28;12(1):130
pubmed: 24165569
Biochem J. 2005 Aug 15;390(Pt 1):189-97
pubmed: 15823097
Cell. 2011 May 27;145(5):732-44
pubmed: 21620138
Theranostics. 2018 Jan 1;8(2):423-436
pubmed: 29290818
Lancet Oncol. 2022 Sep;23(9):1133-1144
pubmed: 36055304
Cancer Manag Res. 2020 Feb 12;12:1079-1088
pubmed: 32104088
J Clin Invest. 2013 Sep;123(9):3685-92
pubmed: 23999443
J Biol Chem. 2002 Dec 6;277(49):47014-21
pubmed: 12354771
Nature. 2012 Jul 19;487(7407):380-4
pubmed: 22801492
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Mol Cell Biol. 2015 Dec;35(24):4096-109
pubmed: 26391953
Clin Cancer Res. 2013 Jan 1;19(1):73-84
pubmed: 23147995
Dig Dis Sci. 2011 Jul;56(7):2009-16
pubmed: 21221794
Tumour Biol. 2014 Mar;35(3):2607-17
pubmed: 24318988
Cancers (Basel). 2022 Aug 22;14(16):
pubmed: 36011051
Acta Neuropathol Commun. 2020 May 14;8(1):70
pubmed: 32410663
Am J Transl Res. 2020 Aug 15;12(8):4108-4126
pubmed: 32913492
J Exp Clin Cancer Res. 2020 Jun 1;39(1):98
pubmed: 32487203
Clin Cancer Res. 2016 Jun 1;22(11):2791-801
pubmed: 26783287
Dis Markers. 2015;2015:345080
pubmed: 26693202
Biochem Soc Trans. 2016 Aug 15;44(4):979-86
pubmed: 27528742
Br J Cancer. 2013 May 28;108(10):2033-8
pubmed: 23652305
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2042-2047
pubmed: 31119955
Oncol Rep. 2019 Nov;42(5):1635-1646
pubmed: 31432176
Clin Cancer Res. 2003 Feb;9(2):802-11
pubmed: 12576453
Nucleic Acids Res. 1989 Oct 25;17(20):8390
pubmed: 2813076
Cancer Metab. 2017 Jul 4;5:5
pubmed: 28680592
J Cell Biochem. 2020 Nov;121(11):4377-4385
pubmed: 31904147
Cancer. 2007 Jun 1;109(11):2257-67
pubmed: 17440983
Oncoscience. 2014 Jan 03;1(2):117-31
pubmed: 25594006
Nat Rev Urol. 2019 Sep;16(9):539-552
pubmed: 31278395
Int J Mol Sci. 2015 Jan 30;16(2):3148-62
pubmed: 25647415
Cancer Manag Res. 2019 Aug 14;11:7657-7672
pubmed: 31616182
Nat Commun. 2016 Jul 07;7:12098
pubmed: 27384883
Bull Exp Biol Med. 2021 Nov;172(1):67-71
pubmed: 34792716
Sci Rep. 2015 Jan 05;5:7610
pubmed: 25556603
Oncogene. 2015 Jan 22;34(4):413-23
pubmed: 24469061
Mol Med Rep. 2017 Mar;15(3):1387-1392
pubmed: 28098887
Oncol Rep. 2019 Apr;41(4):2137-2147
pubmed: 30816499
Environ Toxicol Pharmacol. 2018 Sep;62:227-233
pubmed: 30098579
Oncotarget. 2016 Feb 23;7(8):8726-42
pubmed: 26646586
Cancer Res. 2011 May 15;71(10):3552-62
pubmed: 21444677
Exp Mol Med. 2019 Jan 17;51(1):1-10
pubmed: 30700696
Int J Mol Sci. 2020 Sep 28;21(19):
pubmed: 32998233
Hepatology. 2015 Sep;62(3):801-15
pubmed: 25953743
Biomed Pharmacother. 2017 Apr;88:443-448
pubmed: 28122310
PLoS One. 2014 Nov 26;9(11):e114096
pubmed: 25426861
J Exp Clin Cancer Res. 2016 Sep 05;35(1):132
pubmed: 27596137
Oncol Lett. 2016 Jul;12(1):715-720
pubmed: 27347205
FEBS Lett. 2014 Aug 25;588(17):3274-81
pubmed: 25064845
Mol Biol (Mosk). 2018 Sep-Oct;52(5):801-809
pubmed: 30363055
Int J Mol Med. 2012 Sep;30(3):495-501
pubmed: 22735690
Cancers (Basel). 2021 Nov 26;13(23):
pubmed: 34885060
J Environ Public Health. 2023 Feb 6;2023:8405945
pubmed: 36793506
PeerJ. 2022 Jan 04;10:e12493
pubmed: 35036081
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Diagnostics (Basel). 2020 Jan 08;10(1):
pubmed: 31936274
Am J Cancer Res. 2016 Aug 01;6(8):1741-57
pubmed: 27648362
Urol Oncol. 2022 Nov;40(11):495.e1-495.e10
pubmed: 35973929
Biochem Biophys Res Commun. 2008 Feb 22;366(4):1054-60
pubmed: 18155155
Curr Pharm Des. 2010;16(29):3255-63
pubmed: 20819068
Exp Ther Med. 2014 Jun;7(6):1757-1761
pubmed: 24926380
Thorac Cancer. 2019 Apr;10(4):676-685
pubmed: 30710412
Anal Biochem. 2008 Jun 1;377(1):62-71
pubmed: 18384736
Cancer Res. 2000 Dec 15;60(24):7075-83
pubmed: 11156414
Int J Mol Med. 2014 Apr;33(4):950-6
pubmed: 24481267
Cancers (Basel). 2019 Jun 14;11(6):
pubmed: 31207938
Cell Metab. 2011 Dec 7;14(6):768-79
pubmed: 22100406
Eur J Cancer. 2010 Dec;46(18):3141-8
pubmed: 20709527
Ren Fail. 2016 Sep;38(8):1199-205
pubmed: 27453328